More on VRCA

- Summary
- Chart
- Profile
- Historical

Data

- Earnings (-2,100.0% Growth)
- Ratings (6.7 Score)
- FDA

Upcoming Events

- Earnings (8/11/26)

News

- Analyst Ratings
- Earnings Related
- Guidance
- Insider Trades
- Mgmt Changes
- M & A
- Retail Sales
- Rumors
- Stock Buybacks
More...

Verrica Pharmaceuticals Inc. (NQ:VRCA)
Delayed: 5.18 -0.22 (4.07%)
Prev. Close $5.40  
Open$5.35 
52 Wk High$ 
52 Wk Low$ 
Day High$5.79 
Day Low$5.00 
P/E N/A  
EPS$ 
Volume30,912 

Friends, Peers and Foes (?): ESPR TVTX (more...)

Jul 21, 2026 08:00 AM Verrica Pharma signs Israel deal for skin disease treatment YCANTH
Jul 21, 2026 08:00 AM Verrica Pharmaceuticals and Medomie Pharma Enter into Exclusive Distribution, Marketing and Supply Agreement to Commercialize YCANTH® for the Treatment of Molluscum Contagiosum in Israel
Jun 23, 2026 06:53 AM H.C. Wainwright Reiterates Buy Rating on Verrica Pharmaceuticals (VRCA)
Jun 22, 2026 08:05 AM Verrica doses first U.S. patient in COVE-3 trial for common warts
Jun 22, 2026 08:05 AM Verrica Pharmaceuticals Announces First U.S. Patient Dosed in the Second Pivotal Clinical Trial (COVE-3) of its Phase 3 Program Evaluating YCANTH® (VP-102) for the Treatment of Common Warts 
Jun 9, 2026 04:16 PM Form 4 Verrica Pharmaceuticals For: Jun 05 Filed by: Nguyen Diem
Jun 9, 2026 04:16 PM Form 4 Verrica Pharmaceuticals For: Jun 05 Filed by: Eichenfield Lawrence
Jun 9, 2026 04:16 PM Form 4 Verrica Pharmaceuticals For: Jun 05 Filed by: PRYGOCKI MARK A SR
Jun 9, 2026 04:16 PM Form 4 Verrica Pharmaceuticals For: Jun 05 Filed by: Rosenberg Noah L.
Jun 9, 2026 04:15 PM Form 4 Verrica Pharmaceuticals For: Jun 05 Filed by: Rieger Jayson
View All Articles

Entities mentioned with VRCA

View All Entities